Recurrently mutated genes in DLBCL are associated with treatment response to BV plus Len. Genomic landscape of trial patients. Genes were mutated in 3 or more patients (34 of 92 mutated genes for 22 of 37 patients) among the 150 recurrently mutated putative driver genes previously identified.